Biotech is growing more complex as western start-ups race to source Asian assets, even as geopolitical tensions challenge globalization, data sharing and cross-border talent exchange. What’s next for European biotech? Can it rise to these current challenges? Can it match the growing competition and walk the fine line of geopolitics?
Bio€quity Europe is the destination event for biopharma decision-makers to network, partner and debate critical issues facing the biotech industry. It is celebrating its 25th anniversary edition right here in Bruges, with MEDVIA and flandersbio acting as co-organizers!
Find us in these sessions:
13 May – Welcome to BioEquity Europe 2025
Our CEO, Ann Van Gysel, joins BioCentury and the EBD Group to welcome you to the 25th anniversary edition of BioEquity, held in Belgium for only the second time!
13 May – Regional Host Session: A New Era of Cross-sector Financing in Healthtech and Biotech?
We chair this panel on collaborative investment strategies featuring our CEO Ann Van Gysel and our Chair of the Board Jérôme Van Biervliet, Managing Director of VIB
12 May – Ecosystem visit to Ghent
Our international guests are invited to hop aboard our bus to Ghent, where we will explore the Tech Lane Science Park and land at the state-of-the-art headquarters of Flanders’ biotechnology research institute VIB. Visitors will meet players from Ghent’s biotech ecosystem, enjoy lunch, then get to know companies and research groups from the Antwerp area.
We can offer a discount to Bio€quity for our members – contact us for the code!
Bringing BioEquity to Flanders is the result of the efforts of MEDVIA, Flanders Investment & Trade, Flanders.bio and VIB. It will solidify our commitment to building bridges between biotech, medtech and digital health – the focus of MEDVIA’s 2024 Strategic Position paper.
